Elapegademase-lvlr

(Revcovi®)

Elapegademase-lvlr

Drug updated on 1/4/2024

Dosage FormInjection (intramuscular: 0.2 mg/kg, 0.4 mg/kg)
Drug ClassRecombinant adenosine deaminase
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • To treat adenosine deaminase severe combined immunity deficiency (ADA-SCID) in pediatric and adult patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Revcovi (elapegademase-lvlr) Prescribing Information.2020Chiesi USA, Inc. Cary, NC